Stock A298380 ABL BIO INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials ABL Bio Inc.

Equities

A298380

KR7298380007

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 18:00:00 2024-06-25 EDT 		5-day change 1st Jan Change
22,300 KRW -3.88% Intraday chart for ABL Bio Inc. +1.36% -9.35%
06-10 ABL Bio, BMS Collaborate on Gastric Cancer Treatment Trial MT
03-25 Biocytogen Pharmaceuticals Co., Ltd. Enters Collaboration with ABL Bio Inc. to Develop New Bispecific Antibody-Drug Conjugates CI

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025
Capitalization 1 1,041,424 1,099,129 1,178,156 1,071,466 -
Enterprise Value (EV) 1 1,041,424 1,099,129 1,178,156 1,071,466 1,071,466
P/E ratio -23.8 x - -473 x -48.7 x -36.4 x
Yield - - - - -
Capitalization / Revenue - 16.8 x 18.5 x 30.6 x 38.3 x
EV / Revenue - 16.8 x 18.5 x 30.6 x 38.3 x
EV / EBITDA - 454 x -2,541 x -48.7 x -35.7 x
EV / FCF - - -44.3 x -12 x -11 x
FCF Yield - - -2.26% -8.31% -9.05%
Price to Book - - 15.8 x 17.9 x 34.1 x
Nbr of stocks (in thousands) 47,123 47,788 47,893 48,048 -
Reference price 2 22,100 23,000 24,600 22,300 22,300
Announcement Date 22-08-12 23-03-15 24-03-13 - -
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025
Net sales 1 - 65.33 63.55 35 28
EBITDA 1 - 2.42 -0.4637 -22 -30
EBIT 1 - 0.1186 -3.002 -24 -31
Operating Margin - 0.18% -4.72% -68.57% -110.71%
Earnings before Tax (EBT) 1 - - -2.489 -22 -29
Net income 1 -43.56 - -2.489 -22 -29
Net margin - - -3.92% -62.86% -103.57%
EPS 2 -927.0 - -52.00 -458.0 -612.0
Free Cash Flow 3 - - -26,622 -89,000 -97,000
FCF margin - - -41,890.61% -254,285.71% -346,428.57%
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 22-08-12 23-03-15 24-03-13 - -
1KRW in Billions2KRW3KRW in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025
Net Debt - - - - -
Net Cash position - - - - -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow 1 - - -26,622 -89,000 -97,000
ROE (net income / shareholders' equity) - - -3.44% -31.2% -64.3%
ROA (Net income/ Total Assets) - - -1.64% -13.8% -22.1%
Assets 2 - - 152.2 159.4 131.2
Book Value Per Share 3 - - 1,561 1,248 654.0
Cash Flow per Share - - - - -
Capex 2 - - 0.85 - -
Capex / Sales - - 1.34% - -
Announcement Date 22-08-12 23-03-15 24-03-13 - -
1KRW in Million2KRW in Billions3KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ABL BIO INC. Stock ABL Bio Inc.
-9.35% 801M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+16.49% 122B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+21.73% 116B
ARGENX SE Stock argenx SE
+22.18% 27.03B
BIONTECH SE Stock BioNTech SE
-21.81% 20.36B
GENMAB A/S Stock Genmab A/S
-16.89% 16.43B
BEIGENE, LTD. Stock BeiGene, Ltd.
-18.81% 15.91B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-44.74% 15.6B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+62.72% 14.94B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.09% 13.59B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. A298380 Stock
  4. Financials ABL Bio Inc.